February 6, 2026: FDA press release FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs signals escalating enforcement posture
The trial involving 18,000 people not yet published as of September 2023 is apparently the first to show that GLP-1 drugs can confer heart health benefits for people who are overweight but don't have diabetes
To get it into a swallowable tablet, Novo Nordisk pairs the drug with an absorption helper called SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate)
The problem with standard capsules
Glucagon-Like Peptide-1 is Involved in Sodium and Water Homeostasis in Humans
Figure 2 3.2.2 Effect of appendicitis on CRC According to the results of IVW, appendicitis did not increase risk of CC: Colon cancer(MRC-IEU)(OR:1.000, 95%CI:0.999-1.001, P=0.641), Colon cancer(Neale lab)(OR:1.000, 95%CI:1.000-1.001, P=0.319)